MiNK Therapeutics, Inc.

INKT

US6036931029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
0.92 ^USD	+2.06%		-3.08%	-14.02%

07-01	MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell Microcap Growth Index	CI
07-01	MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 3000E Growth Index	CI

MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 3000E Growth Index

July 30, 2024

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
NASDAQ COMPOSITE	18,353 PTS	+0.90%	+3.50%	-
S&P 500	5,567 PTS	+0.54%	+1.95%	-
MINK THERAPEUTICS, INC.	0.92 USD	+2.06%	-3.08%	36.22M

Latest news about MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell Microcap Growth Index	06-30	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 3000E Growth Index	06-30	CI
MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	05-22	CI
Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding	05-13	CI
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	05-13	MT
MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding	05-12	CI
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	03-06	CI
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	02-14	CI
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	02-11	CI
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	02-06	CI
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	01-30	CI
Transcript : MiNK Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	11-03	CI
MiNK Therapeutics, Inc. Announces Resignation of as Director	23-10-17	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Index	23-06-23	CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Index	23-06-23	CI
MiNK Therapeutics Says Cell Product Candidate MiNK-215 Showed 'Potent Anti-Tumor Activity' in Preclinical Trial	23-05-18	MT
HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating	23-05-12	MT
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.92 USD

Average target price

8 USD

Spread / Average Target

+769.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MINK THERAPEUTICS, INC.	-14.02%	36.22M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+42.66%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research